AvroBio Inc

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Infobird Co Ltd

Moving Image Technologies

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 9th, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical triali of AVR-RD-04, an investigational gene therapy for cystinosis, at the 18th Annual WORLDSymposium™ in San Diego. The first three patients infused with AVR-RD-04 remain off oral cysteamine, with follow up durations ranging be

AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O'Bryan as chief regulatory officer. Sean brings a wealth of experience in regulatory strategy and product development to AVROBIO, as well as keen insight into the field of cell and gene therapy, where he has spent most of his career. “We are delighted to bring Sean O'Bryan

AVROBIO Announces the Appointment of Sean O'Bryan as Chief Regulatory Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen's 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu

AVROBIO to Present at Cowen's 2nd Annual Genetic Medicines Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as well as data on its

AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022

AVROBIO, Inc. (AVRO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over AVROBIO, Inc. (AVRO), Here's Why It's a 'Buy' Now

AVROBIO, Inc. (AVRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 44.1% in 4 Weeks

The stock price of Avrobio Inc (NASDAQ: AVRO) fell by 36.63% in the most recent trading session. This is why it happened.

Avrobio Stock (AVRO): Why The Price Substantially Fell

AVROBIO Inc (NASDAQ: AVRO) dropped by 30% after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fabry program because of several reasons, including new clinical findings from the most recent patients given the Phase II FAB-GT drug candidate.

AVROBIO down 30% as it reprioritizes pipeline programs

Avrobio Inc (NASDAQ: AVRO) has updated its pipeline deprioritizing its Fabry disease clinical program to focus on other clinical-stage studies in the lysosomal disorder pipeline.  The company has decided after new data from the five most recently dosed patients in Phase 2 FAB-GT clinical trial indicated variable engraftment patterns that could prolong the program's timeline.

Why Avrobio's Shares Are Plunging Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024. The company is deprioritizing its Fabry disease program due to several factors, including new clinical data showing variable engraftment patterns from

AVROBIO Reprioritizes Pipeline Programs

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), Nov. 21-23, 2021, in Sydney, Australia. Other presentations include

AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: Barclays Gene Editing & Gene Therapy Summit Date: Monday, Nov. 15, 2021 Time: 2:30 p.m. ET Stifel 2021 Virtual Healthcare Conference Date: Wednesday, Nov. 17, 2021 Time: 10:00 a.m. ET A live w

AVROBIO to Present at Two Upcoming Investor Conferences in November

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) on Nov. 21-23, 2021, in Sydney, Australia. Clinical and preclinical data from the company's pipeline of lysosomal disorder program

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update. “We believe the data update provided at the 2021 European Society of Gene & Cell Therapy (ESGCT) Virtual Congress in October continues to strengthen the risk/benefit profile of our first-in-class lentiviral gene the

AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome, a rare and seriously debilitating lysosomal disorder that primarily affects young boys.

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a vision to free people from a lifetime of genetic disease, today announced the appointment of Essra Ridha, M.D., MRCP, FFPM, as chief medical officer. Dr. Ridha brings wide-ranging expertise in early- and late-stage clinical development of ex vivo lentiviral gene therapies. As vice president, clinical development at AVROBIO, she has guided the strategic and scientific development

AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will present at the Jefferies Virtual Gene Therapy/Editing Summit at 10:30 a.m. ET on Thursday, Oct. 28, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section of the Company's website at www.

AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies. The data are being presented at the virtual 28th Annual Congress of the European

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present new safety data from AVROBIO's clinical trials in Fabry disease and Gaucher disease type 1 at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 19-22, 2021. Clinical and preclinical data from across the company's pipeline of lysosomal di

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming virtual investor conferences. Citi's 16th Annual BioPharma Virtual Conference Date: Wednesday, Sept. 8 - Friday, Sept. 10, 2021 1x1 meetings only 2021 Wells Fargo Virtual Healthcare Conference Presentation date: Thurs

AVROBIO to Participate at Four Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended June 30, 2021, and provided a business update. “Data from the patients dosed to date across three indications continue to support our first-in-class, one-time investigational gene therapies as potentially transformative treatments for the more than 50,000 people worl

AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: BTIG Virtual Biotechnology Conference 2021 Date: Monday, Aug. 9, 2021 Time: 3:30 p.m. ET 2021 Wedbush PacGrow Healthcare Virtual Conference Panel: Miss Con-GENE-iality - Updates in Gene Tx Date: W

News for AvroBio Inc Stock (AVRO)